Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update – GlobeNewswire (press release)
BZ Weekly |
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
GlobeNewswire (press release) As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Critical Analysis: OpGen (OPGN) and Editas Medicine (EDIT) Financial Newsletter – Zacks |
